Clinical Trial Update: Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes subcutaneous daratumumab, once-weekly carfilzomib, and dexamethasone (DKd) in patients with high-risk smoldering multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Darzalex (daratumumab) (daratumumab)
• Kyprolis (carfilzomib) (carfilzomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING